CC
APGE

Centiva Capital’s Apogee Therapeutics APGE Stock Holding History

Centiva Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65M Buy
+50,102
New +$4.51M 0.06% 226
2024
Q3 		– Sell
-6,437
Closed -$253K – 2110
2024
Q2 		$253K Buy
+6,437
New +$312K ﹤0.01% 1555

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Centiva Capital's APGE Position: Q2 2026 in Review

Centiva Capital opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 50,102 shares worth $6.65M. The stake represents 0.06% of the portfolio and ranks #226 among its holdings. This is a return to the name: Centiva Capital previously reported a position in APGE as recently as Q2 2024.

Centiva Capital first reported a position in APGE in Q2 2024 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Centiva Capital held 50,102 shares of Apogee Therapeutics worth $6.65M as of Q2 2026.
  • Apogee Therapeutics was a new Centiva Capital position in Q2 2026.
  • Apogee Therapeutics made up 0.06% of Centiva Capital's portfolio in Q2 2026, its #226 holding.
  • Centiva Capital first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.